NAC and oxaliplatin-related neuropathy: a small trial reports a short-term benefit

A placebo comparison over four cycles

Peripheral neuropathy caused by oxaliplatin can limit the administration of this chemotherapy. The trial included patients with stage III or high-risk stage II colorectal cancer receiving adjuvant chemotherapy with modified FOLFOX-6.

The 46 participants were randomly assigned to oral NAC or placebo, administered before each oxaliplatin infusion for four cycles. The researchers assessed neuropathy using two scales, as well as pain intensity and its impact on activities.

A signal for neuropathy, but not for pain intensity

The abstract reports results favoring NAC on neuropathy assessments after the first two cycles and at the end of the study treatment. The impact of pain was also reduced compared with placebo, but not its intensity. These two dimensions are therefore not interchangeable.

The differences are reported as statistically significant. However, the abstract provides neither the absolute differences between groups nor their confidence intervals. It therefore remains difficult to judge whether the improvement was meaningful to patients, beyond being statistically detectable.

Biomarkers that do not establish the mechanism

After treatment, blood concentrations of interleukin-6 and neurotensin were lower in the NAC group than in the placebo group. These observations accompany the clinical signal, but they do not demonstrate that changes in these markers explain the changes in neuropathy.

Interleukin-6 also decreased during follow-up in both groups. A decrease observed from before to after treatment is therefore not enough, on its own, to attribute a specific effect to NAC.

Not yet an established strategy during chemotherapy

This small trial provides an encouraging signal in a specific population, not proof of lasting protection. The abstract provides no information on whether the benefit persisted beyond the four cycles, adverse effects, or any potential consequences for anticancer efficacy.

These data do not justify starting NAC on your own during oxaliplatin treatment. Such a combination must be discussed with your oncology team.

What we can take away

NAC may reduce some symptoms of oxaliplatin-related neuropathy in the short term. The size and duration of the benefit, and the safety of the combination, remain to be established.